STP938: A phase 1/2 study of STP938 for adults with relapsed or refractory B-cell and T-cell lymphomas

This trial is testing a drug called STP938 in people with T-cell and B-cell lymphomas that have either come back (relapsed) or not responded to previous treatment (refractory lymphoma).

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05463263 
 

Trial aim and background 

This trial has two aims. The first aim is to see whether STP938 is safe in treating T-cell lymphomas and B-cell lymphomas, and to find out the best dose. The second aim is to find out how effective STP938 is in treating T-cell and B-cell lymphomas.

Participants in this trial will receive the STP938 treatment as a tablet and will have blood samples taken to see the effects of the drug on the lymphoma and body.

This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter

Adults with B-cell or T-cell lymphoma which has returned (relapsed) or not responded to (refractory) two previous treatments may be eligible for this trial.

Locations

Recruitment is taking place in the following UK locations:

  • University Hospitals of Leicester NHS Trust, Leicester
  • Imperial College / Clinical Trials Unit, Hammersmith Hospital, London
  • The Christie, Manchester
  • Nottingham City Hospital, Nottingham
  • Churchill Hospital, Oxford
  • Derriford Hospital, Plymouth
  • The Royal Marsden, Sutton

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT05463263

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.